

820 **WHAT IS CLAIMED IS:**

1. A pharmaceutical composition for the treatment of gastrointestinal disorders comprising:

- 825       a. one or more antifatulent;  
         b. one or more competitive reversible histamine H<sub>1</sub>-receptor antagonist; and  
         c. a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 further comprising one or more prebiotic.

830

3. The pharmaceutical composition of claim 1 further comprising one or more probiotic.

4. The pharmaceutical composition of claim 1, wherein the gastrointestinal  
835 disorder is selected from the group consisting of acid indigestion, colic, diarrhea, heartburn, irritable bowel syndrome, sour stomach, gas associated with the foregoing conditions, peptic ulcer disease of the esophagus, stomach or duodenum, indigestion, flatulence, dyspepsia of unknown origin including cancer of the stomach, infiltrative disease of the stomach including lymphoma, Crohn's disease, eosinophilic granuloma, tuberculosis, syphilis and sarcoidosis,  
840 abdominal lesions, chronic pancreatitis, biliary disease, Zollinger-Ellison syndrome, motion sickness, and otitis media.

5. A method for the treatment of gastrointestinal disorders comprising administering to a subject in need thereof, a therapeutically effective dose of the composition  
845 of claim 1.

6. The method of claim 5 wherein the gastrointestinal disorders are selected from the group consisting of acid indigestion, colic, diarrhea, heartburn, irritable bowel syndrome, sour stomach, gas associated with the foregoing conditions, peptic ulcer disease of the  
850 esophagus, stomach or duodenum, indigestion, flatulence, dyspepsia of unknown origin including cancer of the stomach, infiltrative disease of the stomach including lymphoma,

Crohn's disease, eosinophilic granuloma, tuberculosis, syphilis and sarcoidosis, abdominal lesions, chronic pancreatitis, biliary disease, Zollinger-Ellison syndrome, motion sickness, and otitis media.

855

7. A pharmaceutical composition for the treatment of colic comprising:
  - a. one or more antifatulent;
  - b. one or more competitive histamine H<sub>1</sub>-receptor antagonist; and
  - c. a pharmaceutically acceptable carrier.

860

8. The pharmaceutical composition of claim 7, wherein the antifatulent is selected from the group consisting of maltodextrin and organopolysiloxanes.

865

9. The pharmaceutical composition of claim 8, wherein the antifatulent is an organopolysiloxane selected from the group consisting of dimethicone, dimethylpolysiloxane, methylpolysiloxane and simethicone.

870

10. The pharmaceutical composition of claim 9, wherein the organopolysiloxane is simethicone.

11. The pharmaceutical composition of claim 10, wherein the simethicone is present in an amount from about 40 mg/ml to about 120 mg/ml.

875

12. The pharmaceutical composition of claim 11, wherein the simethicone is present in an amount of about 80 mg/ml.

880

13. The pharmaceutical composition of claim 7, wherein the histamine H<sub>1</sub>-receptor antagonist is selected from the group consisting of acrivastine, astemizole, azatadine, azelastine, bromodiphenhydramine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyproheptadine, desloratadine, dexbrompheniramine, dexchlorpheniramine, diphenhydramine, doxylamine, fexofenadine, hydroxyzine, ketotifen, loratadine, norastemizole, phenindamine, pyrilamine, temelastine, terfenadine, triprolenamine and triprolidine.

14. The pharmaceutical composition of claim 13, wherein the histamine H<sub>1</sub>-  
885 receptor antagonist is diphenhydramine.

15. The pharmaceutical composition of claim 14, wherein the diphenhydramine is  
present in an amount from about 1.0 mg/ml to about 4.0 mg/ml.

890 16. The pharmaceutical composition of claim 15, wherein the diphenhydramine is  
present in an amount of about 2.0 mg/ml.

17. The pharmaceutical composition of claim 7 further comprising one or more  
prebiotic.

895

18. The pharmaceutical composition of claim 17 wherein the prebiotic is selected  
from the group consisting of larch arabinogalactans, lactulose, lactitol, oligosaccharides and  
inulin.

900 19. The pharmaceutical composition of claim 18 wherein the prebiotic is larch  
arabinogalactans.

20. The pharmaceutical composition of claim 19, wherein the larch  
arabinogalactans are present in an amount from about 25 mg/ml to about 500 mg/ml.

905

21. The pharmaceutical composition of claim 20, wherein the larch  
arabinogalactans are present in an amount of about 250 mg/ml.

22. The pharmaceutical composition of claim 7 further comprising one or more  
910 probiotic selected from the group consisting of *Bifidobacterium species* such as  
*Bifidobacterium bifidum*; *Bifidobacterium brevis*, *Bifidobacterium longus*, *Bifidobacterium*  
*infantis*; *Lactobacillus species*, such as, *Lactobacillus acidophilus*, *Lactobacillus bifidus*,  
*Lactobacillus brevis*, *Lactobacillus bulgaricus*, *Lactobacillus casei*, *Lactobacillus delbruekii*,  
*Lactobacillus lactis*, *Lactobacillus plantarum*, *Lactobacillus reuteri*, *Lactobacillus*

915 *rhamnosus, Lactobacillus salivarius; Enterococcus faecium; Saccharomyces boulardii; and Streptococcus thermophilus.*

23. The pharmaceutical composition of claim 7, wherein the composition is substantially free of dyes, alcohols, artificial flavors, artificial sweeteners and artificial  
920 preservatives.

24. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is in a liquid dosage form.

925 25. The pharmaceutical composition of claim 24, wherein the liquid dosage form is a suspension.

26. The pharmaceutical composition of claim 7, wherein the composition is in a solid dosage form.

930

27. A method for the treatment of colic comprising administering to a subject in need thereof one or more antifatulent and one or more competitive histamine H<sub>1</sub>-receptor antagonist.

935 28. The method according to claim 27, wherein the antifatulent is selected from the group consisting of maltodextrin and organopolysiloxanes.

29. The method according to claim 28, wherein the antifatulent is an organopolysiloxane selected from the group consisting of, dimethicone,  
940 dimethylpolysiloxane, methylpolysiloxane and simethicone.

30. The method according to claim 29, wherein the organopolysiloxane is simethicone.

945 31. The method according to claim 30, wherein the simethicone is administered three (3) to six (6) times daily in an amount from about 25 mg/0.6ml to about 50 mg/0.6ml.

32. The method according to claim 31, wherein the simethicone is administered four times daily in an amount of about 40mg/0.6ml.

950

33. The method according to claim 27, wherein the histamine H<sub>1</sub>-receptor antagonist is selected from the group consisting of acrivastine, astemizole, azatadine, azclastine, bromodiphenhydramine, brompheniramine, cetirizine, chlorpheniramine, clematine, cyproheptadine, desloratadine, dexbrompheniramine, dexchlorpheniramine, 955 diphehydramine, doxylamine, fexofenadine, hydroxyzine, ketoffen, loratidine, norastemizole, phenindamine, pyrilamine, temelastine, terfenadine, tripeleennamine and triprolidine.

34. The method according to claim 33, wherein the histamine H<sub>1</sub>-receptor antagonist is diphenhydramine.

960

35. The method according to claim 34, wherein the diphenhydramine is administered three (3) to six (6) times daily in an amount from about 0.50 mg/0.6ml to about 2.0 mg/0.6ml.

965

36. The method according to claim 35, wherein the diphenhydramine is administered four (4) times daily in an amount of about 1.25mg/0.6ml.

37. The method according to claim 27 further comprising administering one or more prebiotic selected from the group consisting of larch arabinogalactans, lactulose, 970 lactitol, oligosaccharides and inulin.

38. The method according to claim 37 wherein the prebiotic is larch arabinogalactans.

975

39. The method according to claim 38, wherein the larch arabinogalactans is administered three (3) to six (6) times daily in an amount of about 100mg/0.6ml to about 250mg/0.6ml.

40. The method according to claim 39, wherein the larch arabinogalactans is  
980 administered four times daily in an amount of about 125mg/0.6ml.

41. The method according to claim 27 further comprising administering one or  
more probiotic selected from the group consisting of *Bifidobacterium species* such as  
*Bifidobacterium bifidum*; *Bifidobacterium brevis*, *Bifidobacterium longus*, *Bifidobacterium*  
985 *infantis*; *Lactobacillus species*, such as, *Lactobacillus acidophilus*, *Lactobacillus bifidus*,  
*Lactobacillus brevis*, *Lactobacillus bulgaricus*, *Lactobacillus casei*, *Lactobacillus delbruekii*,  
*Lactobacillus lactis*, *Lactobacillus plantarum*, *Lactobacillus reuteri*, *Lactobacillus*  
*rhamnosus*, *Lactobacillus salivarius*; *Enterococcus faecium*; *Saccharomyces boulardii*; and  
*Streptococcus thermophilus*.

990